An AbbVie schizophrenia drug acquired as part of a multi-billion dollar deal has failed two mid-stage studies, dealing a setback to the company’s plans to compete with a Bristol Myers Squibb ...
Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two mid-stage studies. Truist says that Abbvie’s “pain” is Bristol ...
AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie (ABBV) said that its Phase 2 trial investigating ...
The recent FDA approval of KarXT (Cobenfy), developed by Karuna Therapeutics (a subsidiary of Bristol Myers Squibb), marks a pivotal moment in the treatment of schizophrenia. KarXT, an oral dual M1/M4 ...
Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...
In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...
It’s a frustration for both doctors who treat patients with schizophrenia and for people living with it: the most effective antipsychotic drugs have side effects, so unpleasant patients would rather ...
The Food and Drug Administration approved the first new drug in over 30 years to treat schizophrenia in adults. The new drug Cobenfy, formerly known as KarXT, is manufactured by Bristol Myers Squibb, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results